Market Overview

UPDATE: Credit Suisse Upgrades Medtronic to Outperform on Growth Outlook

Related MDT
Medtronic Micra TPS Meets Global Clinical Trial's Safety and Effectiveness Endpoints
13 Stocks To Watch In The Healthcare Space
Do Not Strike Stryker Out (Seeking Alpha)

Credit Suisse upgraded Medtronic (NYSE: MDT) from Neutral to Outperform and raised the price target from $47.00 to $50.00.

Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line growth reported in FY11 & FY12 and further suggest that the growth-oriented acquisitions (Peak, Salient, KH) and increased emerging markets focus that have taken place during CEO Omar Ishrak's early tenure with the company are moving MDT in the right strategic direction."

Medtronic closed at $43.94 on Wednesday.

Latest Ratings for MDT

Nov 2015Credit SuisseMaintainsOutperform
Oct 2015Evercore ISI GroupUpgradesHoldBuy
Sep 2015JefferiesMaintainsHold

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (MDT)

Get Benzinga's Newsletters